← Oncology Approval Tracker

FDA DECISION ·

Darzalex Faspro + pomalidomide + dexamethasone

daratumumab and hyaluronidase-fihj with pomalidomide and dexamethasone · Janssen Biotech

FDA approvalNew or expanded indicationMultiple myeloma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with multiple myeloma after at least one line that included lenalidomide and a proteasome inhibitor.

LAMPGEN ANALYSIS

Why it matters

The action adds a subcutaneous daratumumab-based triplet after defined prior drug exposure.

What research teams should watch

Verify the two prior drug exposures and distinguish subcutaneous dosing from the intravenous formulation.

PRIMARY RECORDS

Sources